Oruka Therapeutics

Oruka Therapeutics

Yahoo Finance • last month

XBI vs. FBT: Broad Biotech Exposure or Concentrated Bets?

The State Street SPDR S&P Biotech ETF (NYSEMKT:XBI) provides broad exposure to the biotech industry, while the First Trust NYSE Arca Biotechnology Index Fund (NYSEMKT:FBT) offers a much more concentrated, equal-weighted alternative. Biote... Full story

Yahoo Finance • last month

Oruka Q2 Net Loss Expands; Expects Phase 2 EVERLAST-A 28 Week Data Of ORKA-001 At The End Of Q3 2026

(RTTNews) - Oruka Therapeutics, Inc. (ORKA), a clinical-stage biotechnology company that develops biologics for the treatment of chronic skin diseases, reported second-quarter 2026 financial results reflecting a wider net loss and provided... Full story

Yahoo Finance • last month

Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

EVERLAST-A Week 28 data expected at the end of 3Q 2026; 52-week data for all participants expected in December 2026 EVERLAST-B fully enrolled ahead of schedule, with Week 16 data now expected in 4Q 2026 Phase 3 program for ORKA-001 expecte... Full story

Yahoo Finance • last month

iShares Global Healthcare ETF vs State Street SPDR Biotech ETF. Which Healthcare-Focused Fund Will Bring You Profits in 2026 and Beyond?

Investors choosing between iShares Global Healthcare ETF (NYSEMKT:IXJ) and State Street SPDR S&P Biotech ETF (NYSEMKT:XBI) must weigh the high-growth potential of specialized U.S. biotech against a more stable, dividend-paying global healt... Full story

Yahoo Finance • 3 months ago

H.C. Wainwright Keeps Buy Rating on Oruka (ORKA) After Apogee Acquisition News

Oruka Therapeutics, Inc. (NASDAQ:ORKA) is one of the Top 10 Hot Stocks with the Highest Upside Potential. On June 23, H.C. Wainwright reaffirmed its Buy rating on Oruka Therapeutics, Inc. (NASDAQ:ORKA) with a price target of $120 on the st... Full story

Yahoo Finance • 3 months ago

Oruka Stock Is Now Up Nearly 700%. Here's What a $687,000 Insider Sale Could Mean

Arjun Agarwal, Senior Vice President, Finance of Oruka Therapeutics (NASDAQ:ORKA), reported the direct sale of 9,854 shares of Common Stock for proceeds of approximately $687K across June 12 and June 15, 2026, according to the SEC Form 4 f... Full story

Yahoo Finance • 3 months ago

Pre-Market Movers: TNON, ADTX, LNAI See Sharp Moves

(RTTNews) - Biotech companies are seeing significant pre-market activity this Monday. Pre-market movers give traders an early read on momentum, sentiment, and potential volatility for the trading day. Price swings before the opening bell... Full story

Yahoo Finance • 4 months ago

Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120%

Key Points Avidity Partners added 259,700 shares of Enliven Therapeutics in the first quarter; the estimated transaction value was $7.19 million (based on quarterly average pricing). The quarter-end position value increased by $14.33 mill... Full story

Yahoo Finance • 4 months ago

Leerink Partners Lifts PT on Oruka Therapeutics, Inc. (ORKA)

Oruka Therapeutics, Inc. (NASDAQ:ORKA) is one of the best performing healthcare stocks so far in 2026. Leerink Partners lifted the price target on Oruka Therapeutics, Inc. (NASDAQ:ORKA) to $120 from $109 on April 30, reaffirming an Outperf... Full story

Yahoo Finance • 5 months ago

Oruka Therapeutics (ORKA) Reports Positive Phase 2a Results for Psoriasis Treatment ORKA-001

Oruka Therapeutics (NASDAQ:ORKA) is one of the small-cap stocks that are on fire right now. On April 27, Oruka Therapeutics announced positive interim results from its EVERLAST-A Phase 2a trial for ORKA-001, a long-acting monoclonal antibo... Full story

Yahoo Finance • 5 months ago

Oruka Therapeutics prices upsized $700M public offering at $72.50 per share

Oruka Therapeutics (ORKA [https://seekingalpha.com/symbol/ORKA]) has announced an upsized public offering [https://seekingalpha.com/pr/20491699-oruka-therapeutics-announces-pricing-of-upsized-700-million-underwritten-public-offering] of 9.... Full story

Yahoo Finance • 5 months ago

Oruka Therapeutics Prices Upsized $700 Mln Offering To Advance Psoriasis Pipeline

(RTTNews) - Oruka Therapeutics, Inc. (ORKA), has priced an upsized $700.4 million underwritten public offering, strengthening its balance sheet as the company advances two late-stage dermatology programs designed for ultra-infrequent dosin... Full story

Yahoo Finance • 5 months ago

Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering

MENLO PARK, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (Nasdaq: ORKA), a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis and other inflammatory... Full story

Yahoo Finance • 5 months ago

Tech Earnings Optimism Powers Stocks Higher

The S&P 500 Index ($SPX) (SPY) on Monday closed up +0.12%, the Dow Jones Industrial Average ($DOWI) (DIA) closed down -0.13%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +0.01%.  June E-mini S&P futures (ESM26) rose +0.14%, and June E... Full story

Yahoo Finance • 5 months ago

Stocks Slip as Higher Oil Prices Spur Inflation Concerns

The S&P 500 Index ($SPX) (SPY) today is down -0.12%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.14%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.30%.  June E-mini S&P futures (ESM26) are down -0.14%, and June E-mini Na... Full story

Yahoo Finance • 5 months ago

Stocks Pressured by Higher Oil Prices

The S&P 500 Index ($SPX) (SPY) today is unchanged, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.09%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.10%.  June E-mini S&P futures (ESM26) are down -0.02%, and June E-mini Nasdaq... Full story

Yahoo Finance • 5 months ago

How A Small Biotech Name Just Rattled AbbVie's $18 Billion Franchise

Nearly two-thirds of patients who received Oruka Therapeutics' experimental psoriasis treatment had completely clear skin after 16 weeks. Continue Reading... Full story

Yahoo Finance • 5 months ago

Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026

MENLO PARK, Calif., April 26, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin... Full story

Yahoo Finance • 5 months ago

Apellis Pharmaceuticals is the most overbought healthcare stock as Q1 earnings roll on

[Heart Health Concept] Eoneren/E+ via Getty Images As the market moves into the second week of Q1 earnings, we look at the most overbought stocks in the healthcare sector. Below is a list of the top 10 healthcare stocks ranked based on t... Full story

Yahoo Finance • 5 months ago

Oruka Therapeutics price target raised to $85 from $45 at Wedbush

Wedbush raised the firm’s price target on Oruka Therapeutics (ORKA) to $85 from $45 and keeps an Outperform rating on the shares. The firm reviewed anticipated benchmarks and stock setup for upcoming induction data from the Phase 2a EVERLA... Full story